Royalty Pharma Completes Internal Acquisition of RP Management

Royalty Pharma plc successfully completed the acquisition of RP Management, its external manager, marking a significant milestone in its evolution. Approved by 99.9% of shareholders, this acquisition transforms Royalty Pharma's corporate structure by internalizing its management, thus reinforcing its commitment to transparency, accountability, and growth. The updated structure positions Royalty Pharma to meet substantial capital needs in the life sciences industry. The company plans to update financial guidance to reflect this change. Founded in 1996, Royalty Pharma is a major purchaser of biopharmaceutical royalties, supporting innovation directly via co-funding of clinical trials, and indirectly through royalty acquisitions. It holds a diversified portfolio benefiting from top-line sales of prominent therapies. The internalization abolishes quarterly management fees previously paid, enhancing economic returns and enabling greater governance and shareholder alignment.